Managing accelerated timelines in manufacturing high-potency drugs. Highly potent API (HPAPI) drugs make up a growing percentage of the small molecule drug development pipeline and this group of products is growing faster than the overall small molecule segment,1 largely due to their usefulness in cancer treatments. Many of these drugs have accelerated timelines for approval and commercial development, which can be challenging for drug developers to keep up with. On the front-end, new technologies… Click Here For Complete Article Text
|
|||||||||||||||||||||||||||
Application Sequencing | |||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||
Company | Product | Process | Other Subjects | Event | Event Date | Location | Publication | Publication Date | Text Descriptor | ||||||||||||||||||
|
|
|
|
|
|
|
|
|